Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules

Journal of Thoracic Disease

Volumn 7, Issue 3, 2015, Pages 422-432

  Gao, Li ^a,b   Xie, Erfu ^a,b   Yu, Tongfu ^a   Chen, Dan ^a,b   Zhang, Lixia ^a,b   Zhang, Bingfeng ^a,b   Wang, Fang ^a,b   Xu, Jian ^a,b   Huang, Peijun ^a,b   Liu, Xisheng ^a   Fang, Bingliang ^c   Pan, Shiyang ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Laboratory Medicine   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

APC; Lung cancer; Quantitative methylation specific PCR; RASSF1A

Indexed keywords

APC PROTEIN; DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; APC GENE; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DNA DETERMINATION; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RASSF1A GENE; TUMOR SUPPRESSOR GENE;

EID: 84928625939     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2015.01.24     Document Type: Article

References (54)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
2. Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004;90:2157-66.
3. Pastorino U. Lung cancer screening. Br J Cancer 2010;102:1681-6.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
5. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17.
6. Pan S, Zhang L, Gao L, et al. The property of methylated APC gene promotor and its influence on lung cancer cell line. Biomed Pharmacother 2009;63:463-8.
7. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011;303:21-8.
8. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. RARβ2 gene methylation level in the circulating DNA from blood of patients with lung cancer. Eur J Cancer Prev 2011;20:453-5.
9. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-5.
10. Yazici H, Terry MB, Cho YH, et al. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2009;18:2723-5.
11. Hibi K, Robinson CR, Booker S, et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.
12. Cho YH, Yazici H, Wu HC, et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res 2010;30:2489-96.
13. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
14. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
15. Van der Auwera I, Elst HJ, Van Laere SJ, et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009;100:1277-86.
16. Matuschek C, Bölke E, Lammering G, et al. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 2010;15:277-86.
17. Chen Z, Fadiel A, Naftolin F, et al. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses 2005;65:956-61.
18. Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006;94:1492-5.
19. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
20. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-8.
21. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11:1219-25.
22. Wang Y, Yu Z, Wang T, et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007;56:289-94.
23. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
24. Oue N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006;106:1250-9.
25. Matsuda Y, Ichida T, Matsuzawa J, et al. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999;116:394-400.
26. Hawes SE, Stern JE, Feng Q, et al. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 2010;69:172-9.
27. Tomizawa Y, Iijima H, Nomoto T, et al. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 2004;46:305-12.
28. Kubo T, Yamamoto H, Ichimura K, et al. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer 2009;65:328-32.
29. Ito M, Ito G, Kondo M, et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005;225:131-9.
30. Xu X, Gammon MD, Zhang Y, et al. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2010;121:685-92.
31. Lind GE, Danielsen SA, Ahlquist T, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011;10:85.
32. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer 2010;9:168-76.
33. Tänzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010;5:e9061.
34. Keller T, Bitterlich N, Hilfenhaus S, et al. Tumour markers in the diagnosis of bronchial carcinoma: new options using fuzzy logic-based tumour marker profiles. J Cancer Res Clin Oncol 1998;124:565-74.
35. Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest 2000;60:259-73.
36. Worthley DL, Whitehall VL, Buttenshaw RL, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010;29:1653-62.
37. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
38. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
39. Liu Z, Zhao J, Chen XF, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer 2008;62:15-22.
40. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-28.
41. Ng EK, Leung CP, Shin VY, et al. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One 2011;6:e22233.
42. Cho YH, Shen J, Gammon MD, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 2012;131:197-205.
43. Ahmed IA, Pusch CM, Hamed T, et al. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet 2010;199:96-100.
44. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
45. Hill VK, Hesson LB, Dansranjavin T, et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010;9:51.
46. Dietrich D, Krispin M, Dietrich J, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer 2010;10:247.
47. Pan SY, Xie EF, Shu YQ, et al. Methylation quantification of adenomatous polyposis coli (APC) gene promoter in plasma of lung cancer patients. Ai Zheng 2009;28:384-9.
48. Zhang LX, Pan SY, Chen D, et al. Effect of adenomatous polyposis coli(APC) promoter methylation on gene transcription in lung cancer cell lines. Ai Zheng 2007;26:576-80.
49. Fleischhacker M, Dietrich D, Liebenberg V, et al. The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev Respir Med 2013;7:363-83.
50. Liu WJ, Tan XH, Guo BP, et al. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Asian Pac J Cancer Prev 2013;14:3719-24.
51. Sheikhnejad R, Zohri M, Shadmehr MB, et al. Detection of aberrant methylation of 10 genes in genomic DNA of lung tumors. Ann Oncol 2013;24:2705-6.
52. van der Drift MA, Prinsen CF, Hol BE, et al. Can free DNA be detected in sputum of lung cancer patients? Lung Cancer 2008;61:385-90.
53. de Fraipont F, Moro-Sibilot D, Michelland S, et al. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 2005;50:199-209.
54. Cirincione R, Lintas C, Conte D, et al. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006;118:1248-53.